Floatz logo

Ny-Eso-1 Plasmid Dna Cancer Vaccine

Bladder Cancer

Ludwig Institute for Cancer ResearchvaccinePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

122 Active assets in the Bladder Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
G1 Therapeutics, Inc.
Phase 3BBB
TRASTUZUMAB
NKGen Biotech, Inc.
Phase 2BB
Carboplatin
G1 Therapeutics, Inc.
Phase 3BB
VINBLASTINE
University of Southern California
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

Ny-Eso-1 Plasmid Dna Cancer Vaccine is also rated in:

sarcomaDormant
CC
Indicative ·
42 / 100
View asset →
esophageal cancerDormant
CC
Indicative ·
40 / 100
View asset →
prostate cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →